Sun Pharma Share Price Gains on Mar 12 Amid Checkpoint Therapeutics Acquisition

Sun Pharmaceutical Industries Limited has been in focus on Wednesday. On March 12, 2025, Sun Pharma share price (NSE: SUNPHARMA) opened at ₹1,662.00, up from its previous close of ₹1,655.30. At 10:14 AM, the share price of Sun Pharma was trading at ₹1,665.50, up by 0.62% on the NSE.

Sun Pharma’s Acquisition of Checkpoint Therapeutics

On March 10, after market hours, Sun Pharma announced that it will acquire Checkpoint Therapeutics, Inc., a Nasdaq-listed immunotherapy and targeted oncology company. 

The pharmaceutical giant will pay an upfront cash payment of $4.1 per share, totaling an estimated $355 million. Additionally, shareholders of Checkpoint will receive a contingent value right of up to $0.7 per share, subject to regulatory milestones.

The additional payout is conditional upon the approval of cosibelimab, an FDA-approved cancer treatment, in the European Union (EU) or specific European markets, including Germany, France, Italy, Spain, or the UK.

The acquisition is expected to be finalised in Q2 2025, following which Sun Pharma will take full ownership of Checkpoint Therapeutics. The upfront offer of $4.1 per share represents a 66% premium over Checkpoint’s last closing price.

Royalty Agreement with Fortress Biotech

As part of the acquisition, Checkpoint, Sun Pharma, and Fortress Biotech – Checkpoint’s controlling stockholder – have entered into a royalty agreement. Following the transaction, Fortress Biotech will receive royalty payments based on future sales of cosibelimab, replacing previously granted royalty rights.

Stock Market Reaction

Following the acquisition announcement, Sun Pharma’s share price saw increased investor interest. On March 11, 2025, the stock opened at ₹1,616.10 and closed at ₹1,655.30, reaching an intraday high of ₹1,663.60.

Conclusion

With this acquisition, Sun Pharma is strengthening its presence in the oncology segment, which could support its long-term growth trajectory.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.